Free Trial

Ampliphi Biosciences (NYSEAMERICAN:APHB) Shares Down 10.1% - Time to Sell?

Ampliphi Biosciences logo with Medical background

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB - Get Free Report) shares fell 10.1% during trading on Monday . The stock traded as low as $1.90 and last traded at $1.95. 45,943 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 842,200 shares. The stock had previously closed at $2.17.

Ampliphi Biosciences Stock Down 0.5%

The company has a fifty day moving average price of $1.41 and a 200 day moving average price of $1.94.

Ampliphi Biosciences Company Profile

(Get Free Report)

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P.

Read More

Should You Invest $1,000 in Ampliphi Biosciences Right Now?

Before you consider Ampliphi Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ampliphi Biosciences wasn't on the list.

While Ampliphi Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines